These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 23633224)
1. Makers of anticancer drugs are "profiteering," say 100 specialists from around the world. Laurance J BMJ; 2013 Apr; 346():f2810. PubMed ID: 23633224 [No Abstract] [Full Text] [Related]
2. Big Pharma Profits and the Public Loses. DeAngelis CD Milbank Q; 2016 Mar; 94(1):30-3. PubMed ID: 26765284 [No Abstract] [Full Text] [Related]
3. Hepatitis C drug maker puts profit ahead of patients, US Senate report charges. McCarthy M BMJ; 2015 Dec; 351():h6573. PubMed ID: 26635239 [No Abstract] [Full Text] [Related]
4. Pricing Cancer Drugs: When Does Pricing Become Profiteering? Kushnick HL AMA J Ethics; 2015 Aug; 17(8):750-3. PubMed ID: 26270874 [No Abstract] [Full Text] [Related]
5. The cost of prescription drugs: rising concerns over equity, fairness and access to essential care. Work DR; Domino ME N C Med J; 2003; 64(6):270-4. PubMed ID: 14983614 [No Abstract] [Full Text] [Related]
6. Indian patients go to court over cancer drug. Murdur G BMJ; 2004 Aug; 329(7463):419. PubMed ID: 15321889 [No Abstract] [Full Text] [Related]
7. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Experts in Chronic Myeloid Leukemia Blood; 2013 May; 121(22):4439-42. PubMed ID: 23620577 [TBL] [Abstract][Full Text] [Related]
9. Higher Drug Prices from Anticompetitive Conduct: Three Case Studies. Carrier MA J Leg Med; 2019; 39(2):151-167. PubMed ID: 31503532 [TBL] [Abstract][Full Text] [Related]
10. How much is more life worth? Brock DW Hastings Cent Rep; 2006; 36(3):17-9. PubMed ID: 16776018 [No Abstract] [Full Text] [Related]
11. [Economic burden for patients with chronic myelogenous leukemia--healthcare economics and medical governance of cancer]. Kodama Y; Kami M Gan To Kagaku Ryoho; 2010 Apr; 37(4):577-81. PubMed ID: 20414010 [TBL] [Abstract][Full Text] [Related]
12. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015. Gambacorti-Passerini C; Piazza R JAMA Oncol; 2015 May; 1(2):143-4. PubMed ID: 26181011 [No Abstract] [Full Text] [Related]
13. Can grapefruit juice decrease the cost of imatinib for the treatment of chronic myelogenous leukemia? Kimura S; Kako S; Wada H; Sakamoto K; Ashizawa M; Sato M; Terasako K; Kikuchi M; Nakasone H; Okuda S; Yamazaki R; Oshima K; Nishida J; Watanabe T; Kanda Y Leuk Res; 2011 Jan; 35(1):e11-2. PubMed ID: 20952061 [No Abstract] [Full Text] [Related]
14. Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe--impact of cost considerations. Gratwohl A; Baldomero H; Schwendener A; Gratwohl M; Urbano-Ispizua A; Frauendorfer K Leukemia; 2007 Mar; 21(3):383-6. PubMed ID: 17311065 [No Abstract] [Full Text] [Related]
15. Do affluent societies have the only options for the best therapy? Gajewski JL; Robinson P Leukemia; 2007 Mar; 21(3):387-8. PubMed ID: 17311066 [No Abstract] [Full Text] [Related]
16. Pricing increases for cancer drugs sparks investigation. Venkatesan P Lancet Oncol; 2017 Jul; 18(7):e372. PubMed ID: 28552213 [No Abstract] [Full Text] [Related]
17. Orphan economics: the downside of supplyside pharmacology. Samson K Ann Neurol; 2008 Sep; 64(3):A13-6. PubMed ID: 18825669 [No Abstract] [Full Text] [Related]
18. When will the U.S. flinch at cancer drug prices? Vanchieri C J Natl Cancer Inst; 2005 May; 97(9):624-6. PubMed ID: 15870428 [No Abstract] [Full Text] [Related]
19. Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients? Goldman J Nat Clin Pract Oncol; 2005 Mar; 2(3):126-7. PubMed ID: 16264901 [No Abstract] [Full Text] [Related]
20. Gleevec (STI-571) for chronic myeloid leukemia. Med Lett Drugs Ther; 2001 Jun; 43(1106):49-50. PubMed ID: 11402258 [No Abstract] [Full Text] [Related] [Next] [New Search]